On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies COVID-19 vaccine, to the 27 European Union (EU) member states in 2021.

This announcement was a result of the European Commission’s (EC) decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17, 2021. This brought the total number of doses to be delivered to the EU to 600 million. COMIRNATY^® was produced in BioNTech’s and Pfizer’s manufacturing sites in Europe.

The Pfizer-BioNTech COVID-19 vaccine was granted conditional marketing authorisation by the European Medicines Agency to prevent coronavirus disease 2019 (COVID-19) in people from 16 years of age. The European Medicines Agency’s (EMA’s) human medicines committee (CHMP) has completed its rigorous evaluation of COMIRNATY^®, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine were available.